Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK)
HKD 2.51
(-0.79%)
HKD 2.51
(-0.79%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 850.73 Million CNY | -17.5% |
| 2022 | 1.03 Billion CNY | -9.57% |
| 2021 | 1.14 Billion CNY | 36.76% |
| 2020 | 833.8 Million CNY | -18.99% |
| 2019 | 1.02 Billion CNY | 39.01% |
| 2018 | 740.42 Million CNY | 48.77% |
| 2017 | 497.69 Million CNY | -19.97% |
| 2016 | 621.87 Million CNY | 7.32% |
| 2015 | 579.46 Million CNY | 23.05% |
| 2014 | 470.9 Million CNY | 13.22% |
| 2013 | 415.92 Million CNY | 78.87% |
| 2012 | 232.52 Million CNY | 73.67% |
| 2011 | 133.89 Million CNY | 44.92% |
| 2010 | 92.39 Million CNY | 49.24% |
| 2009 | 61.9 Million CNY | 93.51% |
| 2008 | 31.99 Million CNY | 28.33% |
| 2007 | 24.92 Million CNY | 26.12% |
| 2006 | 19.76 Million CNY | -1.75% |
| 2005 | 20.11 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 260.47 Million CNY | 76.42% |
| 2024 Q1 | 147.64 Million CNY | 3.41% |
| 2023 Q1 | 189.14 Million CNY | -39.93% |
| 2023 Q2 | 333.68 Million CNY | 76.41% |
| 2023 FY | 850.73 Million CNY | -17.5% |
| 2023 Q3 | 185.13 Million CNY | -44.52% |
| 2023 Q4 | 142.77 Million CNY | -22.88% |
| 2022 Q2 | 130.45 Million CNY | -7.35% |
| 2022 Q4 | 314.89 Million CNY | -29.24% |
| 2022 FY | 1.03 Billion CNY | -9.57% |
| 2022 Q3 | 445 Million CNY | 241.12% |
| 2022 Q1 | 140.8 Million CNY | -68.16% |
| 2021 FY | 1.14 Billion CNY | 36.76% |
| 2021 Q1 | 126.2 Million CNY | -62.62% |
| 2021 Q2 | 272.83 Million CNY | 116.19% |
| 2021 Q3 | 299.07 Million CNY | 9.62% |
| 2021 Q4 | 442.19 Million CNY | 47.85% |
| 2020 FY | 833.8 Million CNY | -18.99% |
| 2020 Q3 | 260.59 Million CNY | 29.72% |
| 2020 Q2 | 200.89 Million CNY | 478.68% |
| 2020 Q1 | 34.71 Million CNY | -91.42% |
| 2020 Q4 | 337.58 Million CNY | 29.54% |
| 2019 Q2 | 307.13 Million CNY | 267.56% |
| 2019 Q1 | 83.56 Million CNY | -62.54% |
| 2019 Q4 | 404.44 Million CNY | 72.72% |
| 2019 FY | 1.02 Billion CNY | 39.01% |
| 2019 Q3 | 234.15 Million CNY | -23.76% |
| 2018 Q4 | 223.06 Million CNY | 0.0% |
| 2018 FY | 740.42 Million CNY | 48.77% |
| 2018 Q2 | 147.85 Million CNY | 0.0% |
| 2018 Q3 | 223.06 Million CNY | 50.87% |
| 2018 Q1 | 147.85 Million CNY | 31.04% |
| 2017 Q3 | 112.82 Million CNY | -17.05% |
| 2017 Q4 | 112.82 Million CNY | 0.0% |
| 2017 Q2 | 136.02 Million CNY | 0.0% |
| 2017 Q1 | 136.02 Million CNY | -28.4% |
| 2017 FY | 497.69 Million CNY | -19.97% |
| 2016 Q3 | 189.98 Million CNY | 57.07% |
| 2016 Q2 | 120.95 Million CNY | 0.0% |
| 2016 Q1 | 120.95 Million CNY | -33.77% |
| 2016 FY | 621.87 Million CNY | 7.32% |
| 2016 Q4 | 189.98 Million CNY | 0.0% |
| 2015 FY | 579.46 Million CNY | 23.05% |
| 2015 Q4 | 182.61 Million CNY | 0.0% |
| 2015 Q2 | 107.11 Million CNY | 0.0% |
| 2015 Q3 | 182.61 Million CNY | 70.49% |
| 2015 Q1 | 107.11 Million CNY | -32.53% |
| 2014 Q3 | 158.76 Million CNY | 107.04% |
| 2014 Q4 | 158.76 Million CNY | 0.0% |
| 2014 FY | 470.9 Million CNY | 13.22% |
| 2014 Q1 | 76.68 Million CNY | -49.54% |
| 2014 Q2 | 76.68 Million CNY | 0.0% |
| 2013 Q2 | 109.9 Million CNY | 133.7% |
| 2013 Q4 | 151.96 Million CNY | 41.99% |
| 2013 FY | 415.92 Million CNY | 78.87% |
| 2013 Q1 | 47.02 Million CNY | -54.22% |
| 2013 Q3 | 107.02 Million CNY | -2.62% |
| 2012 FY | 232.52 Million CNY | 73.67% |
| 2012 Q4 | 102.72 Million CNY | 117.98% |
| 2012 Q3 | 47.12 Million CNY | -26.51% |
| 2012 Q2 | 64.12 Million CNY | 245.54% |
| 2012 Q1 | 18.55 Million CNY | -69.59% |
| 2011 Q3 | 33.81 Million CNY | 14.32% |
| 2011 FY | 133.89 Million CNY | 44.92% |
| 2011 Q1 | 9.46 Million CNY | -75.6% |
| 2011 Q2 | 29.58 Million CNY | 212.64% |
| 2011 Q4 | 61.02 Million CNY | 80.47% |
| 2010 FY | 92.39 Million CNY | 49.24% |
| 2010 Q4 | 38.78 Million CNY | 118.97% |
| 2010 Q3 | 17.71 Million CNY | -21.25% |
| 2010 Q2 | 22.48 Million CNY | 67.72% |
| 2010 Q1 | 13.4 Million CNY | 0.0% |
| 2009 Q2 | 11.78 Million CNY | 0.0% |
| 2009 FY | 61.9 Million CNY | 93.51% |
| 2008 FY | 31.99 Million CNY | 28.33% |
| 2007 FY | 24.92 Million CNY | 26.12% |
| 2006 FY | 19.76 Million CNY | -1.75% |
| 2005 FY | 20.11 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | -228.268% |
| Grand Pharmaceutical Group Limited | 10.52 Billion HKD | 91.921% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | -1339.53% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | -8.528% |
| Qianhai Health Holdings Limited | 961.29 Million HKD | 11.501% |
| Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | 19.211% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | 50.149% |
| Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | -5.145% |
| PuraPharm Corporation Limited | 406.85 Million HKD | -109.098% |
| SSY Group Limited | 6.46 Billion HKD | 86.837% |
| JBM (Healthcare) Limited | 648.41 Million HKD | -31.202% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | 42.04% |
| China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 99.685% |